Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data by Campbell BV et al.
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
Newcastle University ePrints - eprint.ncl.ac.uk 
Campbell BV, Zwam WHV, Goyal M, Menon BK, Dippel DWJ, Demchuk AM, Bracard S, 
White PM, Dávalos A, Majoie CBLM, Lugt AVD, Ford GA, Ossa NPDL, Kelly M, Bourcier R, 
Donnan GA, Roos YBWEM, Bang OY, Nogueira RG, Devlin TG, Berg LAVD, Clarençon F, 
Burns P, Carpenter J, Berkhemer OA, Yavagal DR, Pereira VM, Ducrocq X, Dixit A, 
Quesada H, Epstein J, Davis SM, Jansen O, Rubiera M, Urra X, Micard E, Lingsma HF, 
Naggara O, Brown S, Guillemin F, Muir KW, Oostenbrugge RJV, Saver JL, Jovin TG, Hill 
MD, Mitchell PJ.
Effect of general anaesthesia on functional outcome in patients with anterior circulation 
ischaemic stroke having endovascular thrombectomy versus standard care: a meta-
analysis of individual patient data.  
The Lancet Neurology 2018, 17(1), 47-53. 
Copyright: 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
DOI link to article: 
https://doi.org/10.1016/S1474-4422(17)30407-6  
Date deposited:   
28/11/2017 
Embargo release date: 
16 June 2018  
Effect of general anaesthesia on functional outcome among patients 
with anterior circulation ischaemic stroke undergoing endovascular 
thrombectomy versus standard care: a meta-analysis of individual 
patient data from seven randomised controlled trialsThe Association 
Between General Anaesthesia and Outcome of Endovascular 
Thrombectomy in Pooled Data from Seven Randomised Trials 
 
Bruce C.V. Campbell1 PhD, Wim H. van Zwam2 MD, Professor Mayank 
Goyal3 MD, Bijoy K. Menon3 MD, Professor Diederik W.J. Dippel4 MD, 
Professor Andrew M. Demchuk3 MD, Professor Serge Bracard5 MD, 
Professor Philip White6 MD, Professor Antoni Dávalos7 MD, Professor 
Charles B.L.M. Majoie8 MD, Professor Aad van der Lugt9 MD, Professor Gary 
A. Ford10 FRCP, Natalia Pérez de la Ossa7 MD, Michael Kelly11 MD, Romain 
Bourcier12 MD, Professor Geoffrey A. Donnan13 MD, Professor Yvo B.W.E.M. 
Roos14 MD, Professor Oh Young Bang15 MD, Professor Raul G. Nogueira16 
MD, Thomas G. Devlin17 MD, Lucie A van den Berg14 MD, Frederic 
Clarencon18 MD, Paul Burns19 MD, Professor Jeffrey Carpenter20 MD, Olvert 
A. Berkhemer2,4,8 MD, Dileep R. Yavagal21 MD, Vitor Mendes Pereira22 
MD, Professor Xavier Ducrocq23 MD, Anand Dixit6 MD, Helena Quesada24 
MD, Jonathan Epstein25 MD, Professor Stephen M. Davis1 MD, Professor 
Olav Jansen26 MD, Marta Rubiera27 MD, Xabier Urra28 MD, Emilien Micard29 
MSc, Hester Lingsma30 PhD, Olivier Naggara31 MD, Scott Brown32 PhD, 
Professor Francis Guillemin25* MD, Professor Keith W. Muir33* PhD, Professor 
Robert J. van Oostenbrugge34* MD, Professor Jeffrey L. Saver35* MD, Tudor 
G. Jovin36* MD, Professor Michael D. Hill3* MD, Professor Peter J. Mitchell37* 
MMed for the HERMES collaborators 
 
* have contributed equally. 
1. Department of Medicine and Neurology, Melbourne Brain Centre at the 
Royal Melbourne Hospital, University of Melbourne, Parkville, Australia 
2. Department of Radiology, Maastricht University Medical Center and 
Cardiovascular Research Institute, Maastricht, the Netherlands  
3. Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming 
School of Medicine, University of Calgary, Foothills Hospital, Calgary AB, 
Canada 
4. Department of Neurology, Erasmus MC University Medical Center, 
Rotterdam, the Netherlands. 
5. Department of Diagnostic and Interventional Neuroradiology, INSERM U 
947, University of Lorraine and University Hospital of Nancy, Nancy, 
France 
6. Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK 
7. Department of Neuroscience, Hospital Germans Trias i Pujol, Universitat 
Autònoma de Barcelona, Barcelona, Spain 
8. Department of Radiology, Academic Medical Center, Amsterdam, the 
Netherlands 
9. Department of Radiology, Erasmus MC University Medical Center, 
Rotterdam, the Netherlands. 
10. Division of Medical Sciences, Oxford University Hospitals NHS Trust, 
Oxford University, Oxford, UK 
11. Department of Medical Imaging, University of Saskatchewan, 
Saskatoon, Canada 
12. Department of Neuroradiology, University and University Hospital of 
Nantes, Nantes, France 
13. The Florey Institute of Neuroscience and Mental Health, University of 
Melbourne, Parkville, Australia 
14. Department of Neurology, Academic Medical Center, Amsterdam, the 
Netherlands 
15. Department of Neurology, Samsung Medical Center, Sungkyunkwan 
University School of Medicine, Seoul, South Korea 
16. The Marcus Stroke and Neuroscience Center, Grady Memorial 
Hospital, Department of Neurology, Emory University School of Medicine, 
Atlanta, USA 
17. Department of Neurology, University of Tennessee College of 
Medicine, Chattanooga, USA 
18. Department of Neuroradiology, Pitié-Salpétrière Hospital and Paris 
Pierre et Marie Curie University, Paris, France 
19. Department of Neuroradiology, Royal Victoria Hospital, Belfast, 
Northern Ireland 
20. Department of Radiology, West Virginia University Hospital, West 
Virginia, USA 
21. Department of Neurology and Neurosurgery, University of Miami Miller 
School of Medicine–Jackson Memorial Hospital, Miami, USA  
22. Division of Neuroradiology and Division of Neurosurgery, Departments 
of Medical Imaging and Surgery, Toronto Western Hospital, University 
Health Network, University of Toronto, Toronto, Canada 
23. Department of Neurology, CHR Mercy, Metz, France 
24. Stroke Unit, Hospital de Bellvitge, Barcelona, Spain 
25. Department of Clinical Epidemiology, INSERM CIC-EC 1433, 
University of Lorraine and University Hospital of Nancy, Nancy, France 
26. Institute of Neuroradiology, Universitätsklinikum Kiel, Kiel, Germany 
27. Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain  
28. Stroke Unit, Hospital Clínic, Barcelona, Spain 
29. CIC-IT INSERM 1433, University of Lorraine and University Hospital of 
Nancy, Nancy, France 
30. Department of Public Health, Erasmus MC University Medical Center, 
Rotterdam, the Netherlands 
31. Department of Neuroradiology, Sainte-Anne Hospital and Paris-
Descartes University, INSERM U894, IMABRAIN, Neurosciences and 
Psychiatry Center, Paris, France 
32. Altair Biostatistics, St Louis Park, Minnesota, USA 
33. Institute of Neuroscience & Psychology, University of Glasgow, Queen 
Elizabeth University Hospital, Glasgow, UK 
34. Department of Neurology, Maastricht University Medical Center and 
Cardiovascular Research Institute, Maastricht, the Netherlands 
35. Department of Neurology and Comprehensive Stroke Center, David 
Geffen School of Medicine at the University of California, Los Angeles, Los 
Angeles, California, USA  
36. Stroke Institute, Department of Neurology, University of Pittsburgh 
Medical Center, Pittsburgh, USA 
37. Department of Radiology, Royal Melbourne Hospital, University of 
Melbourne, Parkville, Australia 
 
Cover Title: Effect of general anaesthesia in stroke thrombectomy 
Abstract: 325 342 words 
Manuscript text: 2266 words  
 
Corresponding Author: 
A/Prof Bruce Campbell, Department of Neurology, Royal Melbourne Hospital, 
Grattan St, Parkville Vic 3050, Australia 
Tel: +61 3 9342 8448   Fax: +61 3 9342 8427  
Email: bruce.campbell@mh.org.au 
 
 
  
Abstract 
Background: General anaesthesia (GA) during endovascular thrombectomy 
has been associated with worse patient outcomes in observational studies. 
We examined the association between GA and the outcome of endovascular 
thrombectomy in pooled data from seven available trials. 
Methods: Patient-level data were pooled from randomiszed trials listed in 
Pubmed 1/Jan/2010-31/May/2017 comparing endovascular thrombectomy 
(performed predominantly using predominantly  stent-retrievers) with standard 
care in anterior circulation ischaemic stroke patients (HERMES 
Collaboration). The primary outcome was ordinal analysis of the modified 
Rankin scale (mRS) at 90 days in the GA and non-GA subgroups of 
endovascular-treated patients and patients randomised to standard care, 
adjusted for baseline prognostic variables. An alternative approach using 
propensity-score stratification was also used. To account for between-trial 
variance we used mixed-effects modeling with a random effect for trial 
incorporated in all models.  
Findings: Of 1764 patients, 871 were allocated to endovascular 
thrombectomy. After exclusion of 74 patients (72 who did not undergo the 
procedure and 2 with missing data on anaesthetic strategy), 236/797 (30%) of 
endovascular patients were treated under GA. At baseline, GA patients were 
younger and had shorter time to randomization but similar pre-treatment 
clinical severity compared to non-GA. Endovascular thrombectomy improved 
functional outcome at 3 months versus standard care in both GA (adjusted 
common odds ratio (cOR) 1·52, 95%CI 1·09-2·11, p=0·014) and non-GA 
(adjusted cOR 2·33, 95%CI 1·75-3·10, p<0·001) patients. However, 
outcomes were significantly better for those treated under non-GA versus GA 
(covariate-adjusted cOR 1·53, 95%CI 1·14-2·04, p=0·004; propensity-
stratified cOR 1·44 95%CI 1·08-1·92, p=0·012). The risk of bias and variability 
among studies was assessed to be low. 
Interpretation: Worse outcomes after endovascular thrombectomy were 
associated with GA, after adjustment for baseline prognostic variables. These 
data support avoidance of GA whenever possible. The procedure did, 
however, remain effective versus standard care in patients treated under GA, 
indicating that treatment should not be withheld in those who require 
anaesthesia for medical reasons.  
Funding: The HERMES collaboration was funded by an unrestricted grant 
from Medtronic to the University of Calgary. 
 
Research in context 
Evidence before this study 
We searched Pubmed for studies examining the association of general 
anaesthesia with outcome in stroke patients undergoing endovascular 
thrombectomy between 1 Jan 2000 2010 and- 31 May 2017. Multiple 
observational studies demonstrated worse outcome in patients treated under 
general anaesthesia. Individual randomised trials of thrombectomy versus 
standard care found conflicting results on the effect of general anaesthesia, 
varying between abolition of the thrombectomy treatment effect in MR CLEAN 
and no effect in THRACE. Three single-centre randomised trials of general 
anaesthesia versus conscious sedation found either no difference in 
functional outcome between groups or a slight benefit of general anaesthesia.    
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Added value of this study 
These data from contemporary, high quality randomised trials form the largest 
study to date of the association between general anesthesia and the benefit of 
endovascular thrombectomy versus standard care. We used two different 
approaches to adjustment for baseline imbalances (multivariable logistic 
regression and propensity-score stratification). We found that GA for 
endovascular thrombectomy, as practiced in contemporary clinical care 
across a wide range of expert centers during the randomised trials, was 
associated with worse outcome than avoiding GA, independent of patient co-
morbidities. Patients still benefited from thrombectomy compared to standard 
care when treated under GA.  
 
Implications of all the available evidence 
The requirement for GA due to airway compromise or agitation that threatens 
the quality of revascularization should not deter clinicians from pursuing 
endovascular thrombectomy. The contrast between this analysis and the 
recent randomised trials comparing GA and conscious sedation suggests that, 
when GA is medically necessary, close attention should be paid to minimizing 
anaesthetic delays to commence the procedure and maintaining physiological 
parameters such as blood pressure. A multi-centre randomiszed trial to 
definitively address these issues is warranted. 
 
  
Introduction: 
 
Multiple observational studies have suggested that patients treated with 
endovascular thrombectomy under general anaesthesia (GA) have poorer 
outcomes than those treated without GA.1 However, patients with more 
severe stroke or comorbidities may be more likely to be treated under GA, 
leading to the potential for confounding by indication. In MR CLEAN, sites 
specified their anaesthetic strategy prospectively and analysis of that trial 
found that the beneficial treatment effect of thrombectomy became non-
significant in patients treated under GA.2 These results could potentially lead 
to a reluctance to convert from an awake procedure to GA in cases where 
patient agitation or challenging vascular anatomy are preventing optimal 
revascularization. In contrast, three small single-center randomised trials 
which compared GA, performed using strict protocols to maintain blood 
pressure, with conscious sedation using the same agents at lower doses 
without intubation did not detect a signal of harm, and functional 
independence was either no different or slightly increased in the GA 
patients.3-5 We analysed the pooled individual patient data from seven 
available randomised trials to assess whether a treatment benefit was 
preserved in patients treated under GA in broader contemporary practice. 
 
  
Methods: 
 
The Highly Effective Reperfusion using Multiple Endovascular Devices 
(HERMES) collaboration6 pooled data from We searched Pubmed for 
randomiszed trials published between 1 Jan 2010 and 31 May 2017 
comparing endovascular thrombectomy performed using predominantly stent-
retrievers with standard care in anterior circulation ischaemic stroke patients - 
Pubmed search string: (("randomiszed controlled trial"[Publication Type]) AND 
((thrombectomy[Title/Abstract]) OR (clot retrieval[Title/Abstract]) OR 
intraarterial[Title/Abstract]) AND (stroke[Title/Abstract]) AND 
("2010/01/01"[Date - Publication] : "2017/05/31"[Date - Publication])). The 
Highly Effective Reperfusion using Multiple Endovascular Devices (HERMES) 
collaboration6 pooled individual patient data from the MR CLEAN,7 ESCAPE,8 
EXTEND-IA,9 SWIFT PRIME,10 REVASCAT,11 PISTE12,13 and THRACE14 
trials. All participants provided informed consent according to each trial 
protocol and each study was approved by the local ethics board.  
 
This meta-analysis was prospectively designed by the HERMES executive 
committee but not registered. The study protocol is included in the 
supplementary web appendix. Data were contributed by the authors of all the 
trials meeting eligibility criteria and collated by independent statisticians. All 
data relevant to the analyses presented were part of each study’s individual 
design and data collection and are part of the general HERMES database.  
No standardization or translation of the fields employed for analysis and 
reporting was necessary. After collation of data, key fields were compared to 
original results, including published data.  No major discrepancies were found 
and minor discrepancies were resolved in collaboration with the study 
authors/investigators. The study selection process is outlined in 
supplementary Figure SA1. Variability between studies is described in 
supplementary Table SA1 and heterogeneity assessed in supplementary 
figures SA2-4. Risk of bias in the individual studies was assessed using the 
Cochrane handbook methodology15 and was low for all studies except 
THRACE which used unblinded assessment of day 90 functional outcome 
(supplementary Table SA2). The principal risk of bias derived from differences 
among individual studies’ methods and inclusion criteria. A one-stage 
approach was employed, defined as use of individual patient data with 
analysis including covariates and random study effects to appropriately 
incorporate any between-study differences.  
 
In MR CLEAN, the steering committee gave no recommendations about 
anaesthetic management. Nevertheless, the majority of centers adhered to a 
fixed protocol regarding type of anesthetic management throughout the trial. 
In the other trials, the use of anaesthesia was at the discretion of the treating 
team on a case by case basis, although two trials (ESCAPE and REVASCAT) 
discouraged GA where possible. 
 
Patients treated under GA (sedation with intubation) were identified and their 
baseline characteristics compared to the non-GA patients who were managed 
with or without sedation and not intubated.  
 
The primary outcome was the mRS at 3 months, which was analyzed using 
ordinal logistic regression to obtain the common odds ratio (cOR). Secondary 
outcomes were the proportion of patients reaching independence (mRS 0-2) 
and return to all usual activities (mRS 0-1) and the proportion with early 
neurological recovery defined as a ≥8 point reduction in National Institutes of 
Health Stroke Scale (NIHSS) or reaching 0-1 at 24 hours. Safety outcomes 
were the proportion of patients who had died at 90 days, the proportion with 
symptomatic intracerebral haemorrhage (SICH, as defined by each trial) and 
the proportion with parenchymal haematoma (PH, intracerebral blood clot with 
mass effect). The proportions of endovascular patients with vessel perforation 
and pneumonia were compared between GA and non-GA groups. 
 
Regression analyses were adjusted for baseline prognostic factors including 
age, sex, NIHSS at baseline, ASPECTS, location of occlusion, treatment with 
intravenous alteplase (yes/no) and time to randomization. Treatment was 
included as a variable with three levels: defined as GA, non-GA and controls. 
To account for between-trial variance we used mixed-effects modeling with a 
random effect for trial incorporated in all models. In addition, as a sensitivity 
analysis, propensity scores were constructed using logistic regression with 
GA vs no GA as the outcome and employing the same set of baseline 
variables as in the regression models.  Propensities were then incorporated 
into the outcome model for the ordinal modified Rankin scale (mRS) score by 
stratification into five groups.16 
 
 
Role of the funding source 
An unrestricted grant was provided to the University of Calgary by Medtronic 
who had no role in study design, the collection, analysis or interpretation of 
data, the writing of the report or the decision to submit the paper for 
publication. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
 
Results: 
 
In the pooled data of 1764 patients, 871 were randomised to endovascular 
thrombectomy and 893 to standard medical care. After exclusion of 74 
patients (72 who did not undergo the procedure and 2 with missing data on 
anaesthetic strategy), 236/797 (30%) of endovascular patients were treated 
under GA. At baseline, patients treated under GA were younger and had 
shorter time from stroke onset to randomization than those treated without GA 
(Table 1). Baseline clinical severity (NIHSS) was not significantly different 
between groups although there was a trend to greater severity in the GA 
patients. GA was used in 113/394 (29%) of right hemisphere and 119/392 
(30%) of left hemisphere stroke patients (p=0·64). GA patients were more 
likely to receive alteplase and had a lower rate of diabetes mellitus. 
 
Functional and neurological outcome 
At 3 months, the patients who underwent endovascular treatment had 
significantly greater odds of improved functional outcome versus standard 
medical care in covariate-adjusted analysis in both GA (common odds ratio 
[cOR] 1·52 CI95 1·09-2·11, p=0·014) and non-GA (cOR 2·33 CI95 1·75-3·10, 
p<0·001) groups, Table 2, Figure 1. There was no heterogeneity in the effect 
of GA on outcome among studies, although the small numbers limit power for 
this analysis. The odds of improved outcome using non-GA versus GA were 
significantly greater in ordinal analysis of the mRS, after adjustment for 
baseline prognostic factors (cOR 1·53 CI95 1·14-2·04, p=0·004). For every 
100 patients treated under GA versus no GA, 18 patients would have worse 
functional outcome, including 10 who would not achieve functional 
independence. The propensity-stratified analysis generated similar results and 
the common odds ratio for improved outcome for non-GA vs GA was 1·44, 
CI95 1·08-1·92, p=0·012. Secondary outcomes followed similar trends (Table 
2).  
 
Safety 
The rate of SICH did not differ between endovascular patients treated under 
GA, those treated without GA or standard medical care patients. There was a 
trend towards reduced 90-day mortality was 13.4% in non-GA patients versus 
17.3% in standard medical care (p=0·07) and 17.4% that was not observed in 
GA versus standard medical care patients (Table 2). Pneumonia occurred in a 
similar proportion of GA versus non-GA patients (11·4% versus 8·4% 
p=0·18), although the reported incidence of pneumonia was significantly 
different among studies (p<0·001), likely indicating differences in definition or 
in capture of adverse events. Rates of vVessel perforation were 
similaroccurred in 0.4% in GA (0·4%) versus 1.6% non-GA patients (1·6%, 
p=0·30). 
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Procedural characteristics and time metrics  
The proportion of patients with successful reperfusion post-procedure 
(modified Treatment in Cerebral Infarction mTICI 2b/3 i.e. reperfusion of 
greater than 50% of the affected territory) did not differ between GA and no 
GA patients (75.1% vs 76.1%, p=0.78). The time interval between 
randomization and reperfusion was significantly greater in GA versus non-GA 
patients (median 105 vs 85 min, p<0·001). However, there was an imbalance 
in the time from stroke onset to randomization which was median 5 minutes 
shorter in the GA group (p=0·04) and the difference in total onset to 
reperfusion time between both groups was therefore not significant (median 
302 vs 288 min, p=0·57, Table 1). 
 
Discussion 
 
Patients treated under GA suffered poorer outcomes compared to those 
treated without GA, after adjustment for baseline characteristics. The 
magnitude of this effect was clinically significant – for every 100 patients 
treated under GA versus no GA, 18 patients would have worse functional 
outcome, including 10 who would not achieve functional independence 
However, a significant benefit of endovascular thrombectomy over standard 
care was retained in those patients treated under GA.  
 
The randomised trials differed in their proportion of patients treated under GA 
but the experience in REVASCAT and ESCAPE, which discouraged GA, was 
that <10% of anterior circulation stroke patients had an absolute requirement 
for GA. MR CLEAN has previously reported that GA was associated with 
marked attenuation of treatment effect. It is possible that the lower rate of 
revascularization in MR CLEAN attenuated the potential treatment benefit 
compared to EXTEND-IA and SWIFT PRIME. However, the THRACE trial 
reported no difference in outcomes in patients treated with or without GA 
despite a similar effect size to MR CLEAN.14 
 
The method of GA in these randomised trials was entirely at the discretion of 
the treating team and there were no formal protocols specifying anaesthetic 
agents, blood pressure targets or other aspects of physiological management. 
This is in contrast to the highly protocol-specified approach to both GA and 
conscious sedation in the SIESTA, ANSTROKE and GOLIATH trials.3-5 In 
particular, strict attention to maintaining systolic blood pressure >140mmHg 
throughout the procedure (including during anaesthetic induction) may have 
been critical to preserving collateral blood flow to the ischaemic penumbra 
and preventing a harmful effect of GA. There were also specified criteria to 
prevent hyper or hypoventilation.  
 
Each of the GA vs conscious sedation randomised trials also used the same 
medications in both treatment arms, the difference being lower dose and 
absence of intubation in the conscious sedation group. This contrasts with the 
HERMES non-GA patient group, in which treatment varied between no 
sedative medication at all and use of sedatives and anaesthetic agents but 
without intubation. The use of local anaesthetic agent at the arterial puncture 
site without any sedative agent, which is routine at many institutions, may 
have different implications for patient outcome compared to conscious 
sedation as described in the recent randomised trials. Different anaesthetic 
agents could also potentially vary in their protective or harmful effects on 
ischaemic brain, among other hypothetical differences between approaches.17 
The details of the medications given in the HERMES patients were not 
available for this analysis. 
 
Although the main reasons given for using GA are procedural safety and 
securing the airway, there was no significant difference in the rate of vessel 
perforation or pneumonia between GA and non-GA patients. Our data 
therefore do not support GA as a safer approach to treatment and 
demonstrate the general technical safety of endovascular thrombectomy.  
There are potential advantages of avoiding GA, including the ability to assess 
neurological status during the procedure, reduced intensive care requirements 
post-procedure and reduced costs. In the HERMES trials, GA was also 
associated with a delay in reperfusion. However, this was not the case in the 
randomised trials where a slight delay to start the procedure in GA patients 
(on average  <10 minutes) appeared to be offset by shorter procedural time. 
This may be plausible if reduced patient movement allows more efficient 
roadmap techniques. However, the three centers that performed the 
randomised trials of GA achieved exceptionally fast anaesthetic induction that 
may not be common practice at most institutions. 
  
The main limitation of this study is that the choice to use GA versus non-GA 
was not randomised and the differentiation between medically required GA 
versus elective GA was not recorded in the trial databases. The important 
prognostic variables of age and time from stroke onset to randomization 
favoured the GA group, although the trend tonon-significantly greater clinical 
severity would partially offset that effect. We used two different methods of 
adjustment for baseline imbalances (multivariate regression and propensity-
score stratification) which gave consistent results. Nonetheless, for both 
methods the possibility of unmeasured confounding remains. The anaesthetic 
practices in the HERMES trials were not pre-specified by protocol nor 
recorded in detail but are likely to have been substantially more variable than 
the recent single centre randomiszed trials. However, this also represents a 
strength of our study as results are likely to be generalizable to current clinical 
practice. The risk of bias in component trials was overall assessed to be low. 
 
In conclusion, the HERMES data suggest that GA for endovascular 
thrombectomy, as practiced in contemporary clinical care across a wide range 
of expert centers during the randomised trials, is associated with worse 
outcome than compared to avoiding GA, independent of patient co-
morbidities. Patients still benefited from thrombectomy compared to standard 
care when treated under GA. Therefore, the requirement for GA due to airway 
compromise or agitation that threatens the quality of revascularization should 
not deter clinicians from pursuing endovascular thrombectomy. The contrast 
between the HERMES data and the recent randomised trials comparing GA 
and conscious sedation suggests that, when GA is medically necessary, close 
attention should be paid to minimizing anaesthetic delays to commence the 
procedure and maintaining physiological parameters such as blood pressure. 
A multi-centre randomiszed trial to definitively address these issues is 
warranted.  
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Figure 1 – Distribution of modified Rankin Scale at 3 months in patients 
treated under general anaesthesia versus without general anaesthesia (no 
GA) versus the standard medical care group.  
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Table 1 – Baseline characteristics of endovascular patients treated under general anaesthesia 
(GA) versus without GA (no GA) and those who received standard care. 
Characteristic GA (n=236) No GA (n=561) 
 
p-value 
GA vs no 
GA 
All 
Endovascular 
(n=871) 
All Standard 
Care (n=893) 
Age, mean (SD) 63·8 (14) 66·3 (13·3) 0·015 65·5 (13·5) 65·7 (13·5) 
Female sex % (n) 42·8% (101/236) 48·7% (273/561) 0·14 47·3% (412/871) 47·3% (421/891) 
NIHSS at baseline, median 
(IQR) 
18 (15-21) 17 (14-20) 0·09 17 (14-20) 17 (13-21) 
ASPECTS, median (IQR) 7 (6-8) 8 (7-9) <0·00100
05 
8 (7-9) 8 (7-9) 
Left hemisphere affected % (n) 51·3% (119/232) 49·3% (273/554) 0·64 49·5% (424/856) 50·2% (442/881) 
Directly admitted to treating 
center %(n) 
75·4% (178/236) 77·3% (432/559) 0·57 78·0% (678/869) 75·2% (668/888) 
Onset to randomization, min 
median (IQR) 
179 (137-238) 184 (144-246) 0·04 181 (141-241) 184 (140-250) 
Randomization to reperfusion, 
min, median (IQR) 
105 (80-149) 85 (51-118) <0·0001 92 (61-128) NA 
Onset to reperfusion, min 
median (IQR) 
302 (246-357) 288 (222-358) 0·57 291 (231,357) NA 
Site of arterial occlusion      
    ICA occlusion %(n) 25·0% (59/236) 25·7% (144/561)  
0·13 
24·7% (215/871) 25·4% (227/893) 
    M1 occlusion %(n) 59·7% (141/236) 61·1% (343/561) 61·5% (536/871) 60·1% (537/893) 
    M2 occlusion %(n)  6·4% (15/236)  8·4% (47/561)  7·7% (67/871)  7·2% (64/893) 
    Unknown %(n) 8·9% (21/236) 4·8% (27/561)  6·1% (53/871)  7·2% (64/893) 
Alteplase administered %(n) 92·4% (218/236) 84·3% (473/561) 0·002 87·6% (763/871) 90·6% (809/893) 
Hypertension %(n) 50·9% (119/234) 56·1% (315/561) 0·18 53·6% (465/867) 58·8% (523/890) 
Hyperlipidemia %(n) 29·7% (69/232) 36·9% (202/548) 0·06 35·5% (300/846) 40·2% (351/873) 
Diabetes mellitus %(n) 8·9% (21/236) 18·2% (102/560) <0·00100
09 
15·1% (131/867) 17·5% (156/889) 
Smoking %(n) 39·0% (85/218) 36·3% (183/504) 0·503 37·8% (298/788) 36·6% (300/820) 
 
SD standard deviation, IQR interquartile range, NIHSS National Institutes of Health Stroke Scale 
(standardized neurological examination) ranges from normal (0) to death (42). ASPECTS Alberta 
Stroke Program Early Computed Tomography Score (reflects extent of early ischemic change on CT 
brain: 10 is normal, 0 is involvement of the entire middle cerebral artery territory). ICA internal carotid 
artery, M1 first segment of middle cerebral artery (pre-bifurcation), M2 second segment of middle 
cerebral artery (from bifurcation to the circular sulcus of the insula in the Sylvian fissure). 
Table 2 – Outcomes in patients treated with standard care versus endovascular thrombectomy with or without general anaesthesia (GA)  
Outcome Standard 
Care (n=893) 
Thrombectomy with 
GA (n=236) 
Thrombectomy 
without GA (n=561) 
GA vs Standard * No GA vs Standard *  No GA vs GA * 
Effect size OR 
(95%CI) 
P value Effect size  
OR (95%CI) 
P value Effect size  
OR (95%CI) 
P value 
Primary outcome  
Functional outcome at 90 days (modified 
Rankin Scale – mRS) Ordinal analysis†  – 
median (IQR) – covariate adjusted 
common odds ratio 
 
 
4 (2, 5) 
 
 
3 (2, 4) 
 
 
2 (1, 4) 
 
 
 
1·52 (1·09-2·11) 
 
 
 
0·01 
 
 
 
2·33 (1·75-3·10) 
 
 
 
<0·0001 
 
 
 
1·53 (1·14-2·04) 
 
 
 
0·004 
– propensity-score stratification 
common odds ratio 
   1·42 (1·09-1·84) 0·008 2·21 (1·65-2·95) <0·0001 1·44 (1·08-1·92) 0·01 
Secondary Outcomes 
Independent functional outcome (mRS0-2) 
30·6% 40·2% 50·3% 1·62 (1·16-2·26) 0·005 2·72 (1·99-3·72) <0·0001 1·65 (1·14-2·38) 0·008 
Excellent functional outcome (mRS0-1) 16·6% 22·6% 31·6% 1·53 (1·02-2·31) 0·04 2·72 (2·00-3·69) <0·0001 1·68 (1·12-2·52) 0·01 
Early neurological improvement (NIHSS 
reduction ≥8 points or reaching 0–1 at 
24h) ‡  
23·8% 38·1% 53·2% 2·02 (1·36-3·00 <0·00051 3·92 (2·73-5·62) <0·0001 1·75 (1·23-2·48) 0·002 
Safety          
Death within 90 days 17·3% 17·4% 13·4% 1·01 (0·67-1·52) 0·96 0·73 (0·52-1·02) 0·07 0·71 (0·44-1·14) 0·15 
Symptomatic intracerebral haemorrhage§ 3·5% 4·4% 3·8% 1·19 (0·56-2·51) 0·65 1·14 (0·62-2·10) 0·68 0·95 (0·41-2·19) 0·90 
Parenchymal haematoma (PH) 10·2% 14·3% 11·4% 1·38 (0·86-2·22) 0·19 1·25 (0·72-2·16) 0·42 0·97 (0·60-1·58) 0·90 
OR odds ratio, CI confidence interval, IQR interquartile range 
* adjusted for age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, ASPECTS score, and time from onset to randomization 
† Modified Rankin scale (mRS) ranges from normal (0) to death (6). Analysis combined mRS 5 & 6  
‡ National Institutes of Health Stroke Scale (NIHSS) score (standardized neurological examination) ranges from normal (0) to death (42), 8 point reduction is highly 
clinically significant.  
§ SICH - Symptomatic intracerebral haemorrhage defined by source trial   
 
